Pharmaceuticals, Biotechnology and Life Sciences
Bristol-Myers Squibb and PsiOxus Therapeutics have entered into an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical…
Bristol-Myers Squibb Company has declared an increase of 2.6% percent in the its quarterly dividend, beginning in the first quarter…
Bristol-Myers gets exclusive worldwide rights to develop Nitto’s investigational anti-fibrosis drug
ristol-Myers Squibb Company and Infinity Pharmaceuticals have announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo …
Bristol-Myers Squibb Company and Innate Pharma SA today announced safety data for two Phase I studies conducted by Bristol-Myers Squibb, testing lirilumab in combination with nivolumab or ipilimumab, respectively, in patients with advanced refractory solid tumors.
Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closely watched clinical trial.
Indian pharmaceutical company Natco Pharma Limited has signed a nonexclusive, royalty free licensing agreement with the Medicines Patent Pool and…
Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog.
Bristol-Myers Squibb has entered into a collaboration agreement with UCLA as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S.
Bristol-Myers Squibb Company has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc.